ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.70
−2.86%Oct 23, 2026, 13:00 UTC
Elicio Therapeutics announced results from its randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P).
Source:Sep 24, 2026, 12:00 UTC
Elicio Therapeutics announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P (camupepimut) in resected pancreatic ductal adenocarcinoma were selected for a late-breaking Proffered Paper oral presentation at the ESMO Congress 2026 in Madrid, Spain.
Source:Jul 2, 2026, 04:25 UTC
Elicio Therapeutics priced a registered direct offering of 4,380,313 shares of common stock for gross proceeds of approximately $15 million.
Jun 17, 2026, 16:43 UTC
Elicio Therapeutics reported clinical observations for its ELI-002 7P cancer drug, indicating durable responses.
Source:Jun 15, 2026, 13:58 UTC
Elicio Therapeutics shares fell about 73% in early trading on Monday after its pancreatic cancer therapy failed a mid-stage study.
Source: